



**Press release**

**Synairgen plc**  
(‘Synairgen’ or the ‘Company’)

## **Posting of Annual Report and Notice of AGM**

**Southampton, UK** – 17 May 2018: Synairgen (LSE: SNG), the respiratory drug discovery and development company, announces that on 17 May 2018 it posted its full Audited Report and Accounts for the twelve months ended 31 December 2017 (the “Annual Report”) to its shareholders together with the Notice of Annual General Meeting (“AGM”). The Annual Report and Notice of AGM are also available on the Company’s website [www.synairgen.com](http://www.synairgen.com).

The AGM will be held at the offices of Fladgate LLP, 16 Great Queen Street, London WC2B 5DG on 22 June 2018 at 11 am.

- Ends -

**For further enquiries, please contact:**

**Synairgen plc**

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

**finnCap**

Geoff Nash, Max Bullen-Smith (Corporate Finance)

Stephen Norcross (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

**Consilium Strategic Communications (Financial Media and Investor Relations)**

Mary-Jane Elliott / Sukaina Virji / Laura Thornton

[synairgen@consilium-comms.com](mailto:synairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5701

**Notes for Editors**

**About Synairgen**

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses *in vitro* and *ex vivo* models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen’s business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis

(IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a £5 million upfront payment and circa 17% of any future partnering proceeds from all fibrotic indications. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see [www.synairgen.com](http://www.synairgen.com)